

## Steady Growth in Q3 2010

- **Increasing interest of Stentys' innovative stents among European cardiologists following positive results of the APPOSITION II study**

**Stentys (FR0010949404 – STNT), a medical technology company that markets a new generation of innovative stents to treat acute myocardial infarction, today reports its third-quarter revenues and nine-month year-to-date revenues.**

- **Quarterly and year-to-date revenues\***

<i>In € thousands</i>	<b>H1 SALES 2010</b>	<b>Q3 2010</b>	<b>9M YTD 2010</b>
<b>Revenues**</b>	72.2	87.5	159.7

*\*The company began to sell its products at the start of 2010. Therefore, no revenues were generated in 2009.*

*\*\*unaudited*

Revenues for the third quarter of 2010 came to €87,500 compared with €72,200 over the first six months of the year. This strong revenue growth relates to Stentys beginning to market its innovative stents in Germany and the ramp-up of sales in the Netherlands.

- **Recent events**

Stentys' strategy is to make its technology the standard of care in heart attack treatment and step up the commercialization of its products.

- Enhancing the medical value of Stentys' stents

On September 22, Stentys reported the results of the Apposition II international clinical trial conducted on 80 patients in six countries. The study indisputably demonstrated that the Stentys stents eliminate malapposition compared with conventional stents, and therefore represents a major breakthrough since malapposition exposes patients to serious risks of recurrence of the infarction.

- Successful IPO

On 22 October 2010, Stentys announced the success of its IPO, listing its shares on Compartment C of NYSE Euronext Paris. Stentys raised €22.7 million from the IPO, bringing the funds needed to establish its self-apposing stent as the standard of care in heart attack treatment. The market for coronary stents in the treatment of myocardial infarction is estimated at \$2.3 billion.

- **Next press release**

Fourth quarter and annual sales press release will be issued on February 8, 2011.

Gonzague Issenmann, Chief Executive Officer and co-founder of Stentys, concludes: "*Stentys' self-apposing stent addresses an unmet medical need with the elimination of malapposition that is associated with the risk of a second heart attack less than one month after the first one. The revenue growth, six months after the product was launched in just two countries, confirms the increasing interest for the technology among key opinion leaders.*"

### **About Stentys**

Based in Princeton, N.J., and Paris, Stentys has developed a new generation of stents to treat acute myocardial infarction (AMI). Founded by Jacques Séguin, M.D., Ph.D., and Gonzague Issenmann, Stentys received the CE mark for its flagship products in 2010. Its self-apposing stents adapt to the anatomic changes of the arteries in the post-infarction phase and thus prevent the malapposition problems associated with conventional stents. Stentys has commenced its marketing activities in several European countries.

***More information on [www.stentys.com](http://www.stentys.com)***

Contacts:

#### **Stentys**

Stanislas Piot

CFO

Tel.: +33 (0)1 44 53 99 42

[stan.p@stentys.com](mailto:stan.p@stentys.com)

#### **NewCap.**

Investor relations & Financial Communications

Axelle Vuillermet / Pierre Laurent

Tel.: +33 (0)1 44 71 94 94

[stentys@newcap.fr](mailto:stentys@newcap.fr)

STENTYS is listed on NYSE Euronext Paris  
ISIN : FR0010949404 – STNT